Claire Ambery

482 total citations
25 papers, 294 citations indexed

About

Claire Ambery is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Claire Ambery has authored 25 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 15 papers in Physiology and 4 papers in Molecular Biology. Recurrent topics in Claire Ambery's work include Asthma and respiratory diseases (15 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Inhalation and Respiratory Drug Delivery (7 papers). Claire Ambery is often cited by papers focused on Asthma and respiratory diseases (15 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Inhalation and Respiratory Drug Delivery (7 papers). Claire Ambery collaborates with scholars based in United Kingdom, United States and Sweden. Claire Ambery's co-authors include Virginia Norris, Peter T. Daley‐Yates, Oliver Kornmann, Eric D. Bateman, B. McQuade, Kevin Smart, Rekha Chaudhuri, Jane Lafferty, Daphne Tsitoura and William Powley and has published in prestigious journals such as European Respiratory Journal, Pharmaceutical Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Claire Ambery

25 papers receiving 290 citations

Peers

Countries citing papers authored by Claire Ambery

Since Specialization

Citations

This map shows the geographic impact of Claire Ambery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Ambery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Ambery more than expected).

Fields of papers citing papers by Claire Ambery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Ambery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Ambery. The network helps show where Claire Ambery may publish in the future.

Co-authorship network of co-authors of Claire Ambery

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Ambery. A scholar is included among the top collaborators of Claire Ambery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Ambery. Claire Ambery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials 2023 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Claire Ambery, Shuying Yang, Misba Beerahee, Elodie L. Plan, Mats O. Karlsson	3
2	General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children 2022 ·British Journal of Clinical Pharmacology ·Naïm Bouazza, Aristides Dokoumetzidis, Catherijne A. J. Knibbe, Saskia N. de Wildt, Claire Ambery, Pieter De Cock, Elke Gasthuys, Frantz Foissac, Saı̈k Urien, Anna‐Karin Hamberg, Italo Poggesi, Wei Zhao, An Vermeulen, Joseph F. Standing, Jean‐Marc Tréluyer, (unknown)	2
3	Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients 2022 ·Pharmaceutical Research ·(unknown), Claire Ambery, Shuying Yang, Misba Beerahee, Elodie L. Plan, Mats O. Karlsson	2
4	Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial 2021 ·The AAPS Journal ·(unknown), Claire Ambery, Shuying Yang, Maggie Tabberer, Misba Beerahee, Elodie L. Plan, Mats O. Karlsson	3
5	Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK 2020 ·Pharmaceutical Research ·Richard Lloyd, (unknown), Jackie C. Bloomer, Stephen Charles, James Butler, Alan Paul, Xiaofeng Zhu, Bruce E. Miller, (unknown), Alison Donald, Ruth Tal‐Singer, Claire Ambery	9
6	A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients 2019 ·The AAPS Journal ·Eva Germovsek, Claire Ambery, Shuying Yang, Misba Beerahee, Mats O. Karlsson, Elodie L. Plan	3
7	Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly Participants 2019 ·Clinical Pharmacology in Drug Development ·Takayuki Iida, (unknown), (unknown), (unknown), (unknown), Claire Ambery, Bruce E. Miller, Aili L. Lazaar, (unknown)	1
8	Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology 2018 ·Toxicological Sciences ·Aliénor Berges, (unknown), (unknown), Lia Liefaard, Claire Ambery, Stefano Zamuner, Chao Chen, Émilie Hénin	3
9	Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations 2017 ·European Journal of Pharmaceutics and Biopharmaceutics ·Jackie C. Bloomer, Claire Ambery, Bruce E. Miller, Paul Connolly, (unknown), (unknown), Neil S. Hodnett, (unknown), James L. Kreindler, Richard Lloyd, W. Stephen Matthews, John Yonchuk, Aili L. Lazaar	18
10	Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial 2015 ·Drugs in R&D ·Claire Ambery, Pascal Wielders, Andrea Ludwig-Sengpiel, Robert Chan, John Riley	7
11	The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers 2014 ·European Journal of Drug Metabolism and Pharmacokinetics ·Bruce E. Miller, Kevin Smart, Sunil Mistry, Claire Ambery, Jackie C. Bloomer, Paul Connolly, (unknown), (unknown), (unknown), Aili L. Lazaar	15
12	Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor 2014 ·Pharmacogenetics and Genomics ·Michael Mosteller, Lynn D. Condreay, (unknown), Claire Ambery, Misba Beerahee, Soumitra Ghosh	5
13	Use of Propranolol Blockade to Explore the Pharmacology of GSK961081, a Bi-Functional Bronchodilator, in Healthy Volunteers: Results from Two Randomized Trials 2014 ·Drugs in R&D ·Virginia Norris, Claire Ambery	5
14	Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β₂‐agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers 2014 ·Clinical Pharmacology in Drug Development ·Virginia Norris, Claire Ambery, Trevor Riley	5
15	Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD 2013 ·Pulmonary Pharmacology & Therapeutics ·Eric D. Bateman, Oliver Kornmann, Claire Ambery, Virginia Norris	31
16	Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD 2013 ·Pulmonary Pharmacology & Therapeutics ·Virginia Norris, Claire Ambery	14
17	Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils 2013 ·Pulmonary Pharmacology & Therapeutics ·Rekha Chaudhuri, Virginia Norris, (unknown), (unknown), Claire Ambery, Jane Lafferty, Euan Cameron, Neil C. Thomson	39
18	Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor 2012 ·British Journal of Clinical Pharmacology ·Gretchen Bain, Christopher D. King, (unknown), (unknown), Virginia Norris, Claire Ambery, J. Bentley, M. Yamada, Angelina M. Santini, Jeroen van de Wetering de Rooij, Nicholas Stock, (unknown), John H. Hutchinson, Jilly F. Evans	19
19	The pharmacodynamics of GSK961081 in patients with COPD 2011 ·European Respiratory Journal ·Virginia Norris, Chang‐Qing Zhu, Claire Ambery	8
20	The Efficacy and Tolerability of Two Novel H<sub>1</sub>/H<sub>3</sub> Receptor Antagonists in Seasonal Allergic Rhinitis 2011 ·International Archives of Allergy and Immunology ·Peter T. Daley‐Yates, Claire Ambery, Lisa Sweeney, Joanna Watson, Amanda J. Oliver, B. McQuade	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact